Zimmer M/L Taper Hip Prosthesis with Kinectiv Technology MR Labeling
K182678 · Zimmer, Inc. · LPH · May 31, 2019 · Orthopedic
Device Facts
Record ID
K182678
Device Name
Zimmer M/L Taper Hip Prosthesis with Kinectiv Technology MR Labeling
Applicant
Zimmer, Inc.
Product Code
LPH · Orthopedic
Decision Date
May 31, 2019
Decision
SESE
Submission Type
Traditional
Regulation
21 CFR 888.3358
Device Class
Class 2
Attributes
Therapeutic
Intended Use
Total hip replacement for patients with: severe hip pain and disability due to rheumatoid arthritis, traumatic arthritis, polyarthritis, collagen disorders, avascular necrosis of the femoral head, nonunion of previous fractures of the femur; congenital hip dysplasia, protrusio acetabuli; previously failed endoprostheses, and/or total hip components in the affected extremity and acute femoral neck fractures. Hemi-hip replacement for patients with: fracture dislocation of the hip; elderly, debilitated patients when a total hip replacement is contraindicated; irreducible fractures in which adequate fixation cannot be obtained; certain high subcapital fractures and comminuted femoral neck fractures in the aged; nonunion of fractures; secondary avascular necrosis of the femoral head; pathological fractures of the femoral neck; and osteoarthritis in which the femoral head is primarily affected. The femoral stem is for cementless use only.
Device Story
Zimmer M/L Taper Hip Prosthesis with Kinectiv Technology is a modular hip arthroplasty system. This submission updates labeling to include MR Conditional status. Device consists of femoral stem and modular neck components; implanted by orthopedic surgeons during hip replacement surgery. System provides structural support for hip joint; restores mobility; alleviates pain. MR Conditional status allows patients with these implants to undergo MRI procedures under specific safety conditions. No changes to device materials, design, or dimensions; update limited to Instructions for Use and package labeling to ensure patient safety in MR environments.
Clinical Evidence
No clinical data provided. Safety and compatibility in MR environment established via non-clinical bench testing per ASTM standards.
Technological Characteristics
Passive hip prosthesis system; cementless femoral stem. Materials and design unchanged from predicates. MR Conditional status verified per ASTM F2503-13. Testing included RF-induced heating (ASTM F2182-11a), image artifact assessment (ASTM F2119-07), and magnetic displacement force (ASTM F2052-14).
Indications for Use
Indicated for total or hemi-hip replacement in patients with severe hip pain/disability due to rheumatoid arthritis, osteoarthritis, traumatic arthritis, polyarthritis, collagen disorders, avascular necrosis, nonunion of femoral fractures, congenital hip dysplasia, protrusio acetabuli, failed previous endoprostheses, fracture dislocation, or acute/pathological femoral neck fractures. Contraindicated for patients where total hip replacement is not suitable (hemi-hip only).
Regulatory Classification
Identification
A hip joint metal/polymer/metal semi-constrained porous-coated uncemented prosthesis is a device intended to be implanted to replace a hip joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across the joint. This generic type of device has a femoral component made of a cobalt-chromium-molybdenum (Co-Cr-Mo) alloy or a titanium-aluminum-vanadium (Ti-6Al-4V) alloy and an acetabular component composed of an ultra-high molecular weight polyethylene articulating bearing surface fixed in a metal shell made of Co-Cr-Mo or Ti-6Al-4V. The femoral stem and acetabular shell have a porous coating made of, in the case of Co-Cr-Mo substrates, beads of the same alloy, and in the case of Ti-6Al-4V substrates, fibers of commercially pure titanium or Ti-6Al-4V alloy. The porous coating has a volume porosity between 30 and 70 percent, an average pore size between 100 and 1,000 microns, interconnecting porosity, and a porous coating thickness between 500 and 1,500 microns. The generic type of device has a design to achieve biological fixation to bone without the use of bone cement.
Predicate Devices
Zimmer M/L Taper Hip Prosthesis With Modular Neck Technology (K063251)
Zimmer M/L Taper Hip Prosthesis With Kinectiv Technology System, Model(S) 7848 Series( Modular Necks), 7713 Series (K071856)
Zimmer M/L Taper Hip Prosthesis With Kinectiv Technology System (K081007)
K200823 — Zimmer, Inc. Hip Joint Prostheses MR Labeling I · Zimmer, Inc. · Jul 9, 2020
K211176 — Smith & Nephew Hip Systems · Smith & Nephew, Inc. · Jul 1, 2022
K222632 — UHR Bipolar Implants, Restoration GAP II Implants · Howmedica Osteonics Corp., Dba Stryker Orthopaedics · Oct 21, 2022
K220731 — Insignia Hip Stem, Restoration Modular 115mm Conical Distal Stem · Stryker · Aug 11, 2022
Submission Summary (Full Text)
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
Zimmer, Inc Caleb Barylski Regulatory Affairs Specialist P.O. Box 708 Warsaw, Indiana 46581-0708 May 31, 2019
Re: K182678
Trade/Device Name: Zimmer M/L Taper Hip Prosthesis with Kinectiv Technology MR Labeling Regulation Number: 21 CFR 888.3358 Regulation Name: Hip Joint Metal/Polymer/Metal Semi-Constrained Porous-Coated Uncemented Prosthesis Regulatory Class: Class II Product Code: LPH, LWJ, LZO, MEH Dated: April 25, 2019 Received: April 29, 2019
Dear Caleb Barylski:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's
{1}------------------------------------------------
requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
CAPT Raquel Peat, PhD, MPH, USPHS FOR Director OHT6: Office of Orthopedic Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
# Indications for Use
510(k) Number (if known)
#### K182678
Device Name
Zimmer M/L Taper Hip Prosthesis with Kinectiv Technology MR Labeling
Indications for Use (Describe)
· Total hip replacement for patients with:
severe hip pain and disability due to rheumatoid arthritis, traumatic arthritis, polyarthritis, collagen disorders, avascular necrosis of the femoral head, nonunion of previous fractures of the femur; congenital hip dysplasia, protrusio acetabuli; previously failed endoprostheses, and/or total hip components in the affected extremity and acute femoral neck fractures.
· Hemi-hip replacement for patients with:
fracture dislocation of the hip; elderly, debilitated patients when a total hip replacement is contraindicated; irreducible fractures in which adequate fixation cannot be obtained; certain high subcapital fractures and comminuted femoral neck fractures in the aged; nonunion of fractures; secondary avascular necrosis of the femoral head; pathological fractures of the femoral neck; and osteoarthritis in which the femoral head is primarily affected.
· The femoral stem is for cementless use only.
X Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
#### CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
## 510(k) Summary
In accordance with 21 CFR §807.92 and the Safe Medical Devices Act of 1990, the following information is provided for the subject Zimmer M/L Taper Hip Prosthesis with Kinectiv Technology MR Labeling 510(k) premarket notification. The submission was prepared in accordance with the FDA guidance document, 'Format for Traditional and Abbreviated 510(k)s', issued on August 12, 2005.
| Sponsor: | Zimmer, Inc.<br>P.O. Box 708<br>Warsaw, IN 46581-0708<br>Establishment Registration Number: 1822565 |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Contact Person: | Caleb Barylski<br>Specialist, Regulatory Affairs<br>Telephone: (574-371-0250)<br>Caleb.Barylski@zimmerbiomet.com |
| Date: | 08-Nov-2018 |
| Subject Device: | Trade Name: Zimmer M/L Taper Hip Prosthesis with<br>Kinectiv Technology MR Labeling<br>Common Name: Hip Prosthesis<br>Classification Name:<br><ul><li>LPH - Prosthesis, Hip, Semi-Constrained, Metal/Polymer, Porous Uncemented (21 CFR 888.3358)</li><li>LWJ - Prosthesis, Hip, Semi-Constrained, Metal/Polymer, Uncemented (21 CFR 888.3360)</li><li>LZO - Prosthesis, Hip, Semi-Constrained, Metal/Ceramic/Polymer, Cemented Or Non-Porous, Uncemented (21 CFR 888.3353)</li><li>MEH - Prosthesis, Hip, Semi-Constrained, Uncemented, Metal / Polymer, Non-Porous, Calcium Phosphate (21 CFR 888.3353)</li></ul> |
| Predicate Device(s): | Zimmer, Inc. |
| | K063251 Zimmer M/L Taper Hip Prosthesis With Modular Neck Technology |
| | K071856 Zimmer M/L Taper Hip Prosthesis With Kinectiv Technology System, Model(S) 7848 Series( Modular Necks), 7713 Series |
| | K081007 Zimmer M/L Taper Hip Prosthesis With Kinectiv Technology System |
{4}------------------------------------------------
## Summary of Technological Characteristics:
The purpose of this submission is to update the Zimmer M/L Taper Hip Prosthesis with Kinectiv Technology Instructions for Use to include MR Conditional labeling within the precaution section. The device package label will also be updated to include the MR Conditional symbol. The addition of MR labeling to the subject devices does not impact indications, materials, design features or dimensions, packaging or sterilization. The subject devices are intended for use in hip arthroplasty. Specific indications for use are below.
{5}------------------------------------------------
## Indications for Use:
## Zimmer M/L Taper Hip Prosthesis with Kinectiv Technology
- Total hip replacement for patients with: .
severe hip pain and disability due to rheumatoid arthritis, osteoarthritis, traumatic arthritis, polyarthritis, collagen disorders, avascular necrosis of the femoral head, nonunion of previous fractures of the femur; congenital hip dysplasia, protrusio acetabuli; previously failed endoprostheses, and/or total hip components in the affected extremity and acute femoral neck fractures.
- . Hemi-hip replacement for patients with:
fracture dislocation of the hip; elderly, debilitated patients when a total hip replacement is contraindicated; irreducible fractures in which adequate fixation cannot be obtained; certain high subcapital fractures and comminuted femoral neck fractures in the aged; nonunion of femoral neck fractures; secondary avascular necrosis of the femoral head; pathological fractures of the femoral neck; and osteoarthritis in which the femoral head is primarily affected.
- The femoral stem is for cementless use only. .
## Summary of Performance Data
#### Non-Clinical Tests: .
Zimmer has performed non-clinical Magnetic Resonance Imaging (MRI) studies on implants which are determined to be MR Conditional in accordance to ASTM F2503-13 Standard Practice for Marking Medical Devices and Other Items for Safety in the Magnetic Resonance Environment. MR Tests included the following:
- RF-induced heating (ASTM F2182-11a)
- Image Artifact (ASTM F2119-07) ●
- . Magnetic Displacement (ASTM 2052-14)
- Clinical Tests: ●
Clinical data was not provided for the subject devices.
- Marketing History and Clinical Publications . A summary of the marketing history and clinical publications related to the subject devices is included.
Substantial Equivalence Conclusion
Non-clinical tests provided in this Traditional 510(k) establish the conditional safety and compatibility of the passive implants in a magnetic resonance (MR) environment. The subject devices are substantially equivalent to the legally marketed predicated devices.
Panel 1
/
Sort by
Ready
Predicate graph will load when search results are available.
Embedding visualization will load when search results are available.
PDF viewer will load when search results are available.
Loading panels...
Select an item from Submissions
Click any panel, subpart, regulation, product code, or device to see details here.
Section Matches
Results will appear here.
Product Code Matches
Results will appear here.
Special Control Matches
Results will appear here.
Loading collections...
Loading
My Alerts
You will receive email notifications based on the filters and frequency you set for each alert.
Sort by:
Create Alert
Search Filters
Agent Token
Create a read-only bearer token for Claude, ChatGPT, or other agents that can call HTTP APIs.